Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9% – Time to Buy?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s share price rose 6.9% during trading on Tuesday . The stock traded as high as $24.80 and last traded at $24.8450. 656,453 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 1,368,493 shares. The stock had previously closed at $23.25.

Analyst Ratings Changes

GLUE has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. upped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Guggenheim lifted their price target on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Zacks Research cut shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday. Finally, Wells Fargo & Company dropped their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Monte Rosa Therapeutics Price Performance

The company has a market capitalization of $2.04 billion, a PE ratio of -16.43 and a beta of 1.56. The business has a 50-day moving average of $19.62 and a 200 day moving average of $19.04.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. As a group, research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Insider Buying and Selling

In other news, COO Jennifer Champoux sold 2,176 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00. Following the transaction, the chief operating officer owned 62,371 shares of the company’s stock, valued at approximately $1,185,049. The trade was a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total transaction of $231,100.00. Following the transaction, the director owned 10,000 shares in the company, valued at $231,100. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,778 shares of company stock worth $1,768,581 in the last 90 days. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $30,000. Russell Investments Group Ltd. purchased a new position in shares of Monte Rosa Therapeutics in the third quarter worth $32,000. Lazard Asset Management LLC grew its stake in Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.